VEMLIDY Drug Patent Profile

Which patents cover Vemlidy, and what generic alternatives are available?

Vemlidy is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-eight patent family members in forty-two countries.

The generic ingredient in VEMLIDY is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Vemlidy

Vemlidy was eligible for patent challenges on November 5, 2019.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (tenofovir alafenamide fumarate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for VEMLIDY

International Patents:	58
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VEMLIDY

Paragraph IV (Patent) Challenges for VEMLIDY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VEMLIDY	Tablets	tenofovir alafenamide fumarate	25 mg	208464	6	2019-11-05

US Patents and Regulatory Information for VEMLIDY

VEMLIDY is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	VEMLIDY	tenofovir alafenamide fumarate	TABLET;ORAL	208464-001	Nov 10, 2016	AB	RX	Yes	Yes					Y
Gilead Sciences Inc	VEMLIDY	tenofovir alafenamide fumarate	TABLET;ORAL	208464-001	Nov 10, 2016	AB	RX	Yes	Yes					Y

International Patents for VEMLIDY

When does loss-of-exclusivity occur for VEMLIDY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

India

Israel

Japan

Lithuania

Mexico

Moldova, Republic of

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VEMLIDY around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	6280162
Japan	2009062383	PRODRUG OF PHOSPHONATE NUCLEOTIDE ANALOGUE AND METHOD FOR SELECTING AND PREPARING THE SAME
Lithuania	2682397

Supplementary Protection Certificates for VEMLIDY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1301519	PA2016009,C1301519	Lithuania		PRODUCT NAME: TENOFOVIRO ALAFENAMIDAS ARBA JO DRUSKA ARBA SOLVATAS, YPATINGAI TENOFOVIRO ALAFENAMIDO FUMARATAS; REGISTRATION NO/DATE: EU/1/15/1061/001 - 002 20151119
1663240	122015000087	Germany		PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN FORM DAVON, DIE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE Z.B EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, UND TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
1663240	2015/053	Ireland		PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT, TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE, AND EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128

Investment Scenario, Market Dynamics, and Financial Trajectory for VEMLIDY (Tenofovir Alafenamide Fumarate)

Last updated: February 3, 2026

Summary

VEMLIDY (tenofovir alafenamide fumarate) is a potent nucleotide reverse transcriptase inhibitor (NRTI) developed by Gilead Sciences for the treatment of chronic hepatitis B (HBV) infection and HIV. Since its approval in 2016, VEMLIDY has gained significant market share due to its improved safety profile and efficacy over predecessor tenofovir disoproxil fumarate (TDF). This analysis explores VEMLIDY’s current market position, growth prospects, competitive landscape, and financial trajectory, with emphasis on investment implications for stakeholders.

---

1. Market Overview and Dynamics

Current Market Position

Parameter	Details
Approved Uses	Chronic HBV, HIV-1 infections
Initial Approval Date	November 2016 (HIV), February 2020 (HBV)
Global Sales (2022)	$3.2 billion (Gilead) (estimated)
Market Share (HIV)	~30% of Gilead’s HIV portfolio (2022)
Market Share (HBV)	Leading agent in HBV, with a dominant share in developed markets

Mechanism of Action and Advantages

Feature	Explanation
Mechanism	Prodrug of tenofovir, designed for targeted delivery into lymphoid and hepatocyte cells
Key Advantages	Improved renal and bone safety profile versus TDF; higher intracellular concentrations with lower plasma levels

Market Drivers

Driver	Impact
Safety Profile	Lower renal and bone toxicity enhances compliance and expands use in sensitive populations
Efficacy	Non-inferior to TDF and TAF in viral suppression
Brand Adoption	Increased prescribing in clinical guidelines for HBV and HIV
Growing Hepatitis C/HBV awareness	Drives demand for effective, safe antivirals
Pricing Dynamics	Premium pricing maintained due to safety benefits

Market Challenges

Challenge	Impact
Generic Competition	Limited in developed markets; emerging in developing regions
Emerging Alternative Therapies	Novel agents and combination therapies could impact growth
Pricing Pressure	Increasing pressure in some markets due to cost-containment policies

---

2. Financial Trajectory and Growth Analysis

Historical Revenue and Sales Data (2016–2022)

Year	Global VEMLIDY Sales (USD billion)	Notes
2016	N/A	Launch year, minimal sales
2017	0.2	Market penetration begins
2018	1.0	Rapid growth, increased adoption
2019	2.5	Dominance in HBV and HIV markets
2020	3.2	Peak sales; steady growth
2021	3.0	Slight plateau, competitive pressures
2022	3.2 (est.)	Market stabilizes, emerging competition

Forecasted Revenue Trajectory (2023–2028)

Year	Projected Sales (USD billion)	Assumptions
2023	3.4	Continued adoption, new indications
2024	3.7	Increased penetration in emerging markets
2025	4.1	Expanded use due to guideline updates
2026	4.5	Licensing agreements and generics in developing nations
2027	4.9	Introduction of new combination therapies
2028	5.3	Mature market with steady growth

Segmental Sales Breakdown

Segment	Percentage of Total Sales	Key Factors
HIV	60%	Steady growth, expanding use in developing countries
HBV	35%	Growing market aligned with enhanced diagnosis programs
Pipeline/Other	5%	Future indications, formulations

---

3. Competitive Landscape

Key Competitors and Market Share

Competitor	Main Products	Estimated Market Share (2022)	Differentiators
Gilead	VEMLIDY, BICNUV, Truvada	60%	Strong R&D pipeline, established presence
GlaxoSmithKline	Epivir HBV	20%	Focused on HBV, older agent
Others	Generic tenofovir formulations, emerging agents	20%	Price competitiveness, pipeline developments

Emerging Alternatives

• Long-acting formulations (injectables, implants)
• Combination therapies with novel antiviral classes
• Gene-editing therapeutic approaches

Key Differentiators

Attribute	VEMLIDY	Competitors
Safety Profile	Superior renal and bone safety	Variable, often inferior
Efficacy	Non-inferior	Similar or superior in recent studies
Formulation	Once-daily oral	Same, with emerging long-acting options

---

4. Investment Considerations

Growth Potential

• Emerging Markets: Increasing access and recognition of HBV and HIV prevalence (WHO reports 296 million people living with chronic HBV globally [1]).
• Guideline Updates: Adoption of VEMLIDY into national and international treatment protocols yields increased sales.
• Pipeline and New Indications: Anticipated approvals for further indications or formulations could serve as catalysts.

Risks

Risk	Impact	Mitigation
Generic Substitutes	Price erosion in developed markets	Strategic pricing and pipeline innovation
Regulatory Changes	Delayed approvals, restrictions	Engagement with authorities, adaptive strategies
Market Saturation & Competition	Reduced margins	Diversifying portfolio, expanding indications

Valuation Metrics and Investment Strategies

Metric	2022 Data	Commentary
P/E Ratio	approx. 18	Moderate, reflects growth potential
Revenue CAGR (2017–2022)	~125%	High-growth trajectory but stabilizing
Market Cap (Gilead)	~$84 billion	VEMLIDY’s contribution sizeable but overshadowed by broader portfolio

Forecasting Financial Outlook

Scenario	Assumptions	Revenue Range (2023–2028)	Rationale
Optimistic	Rapid adoption, new indications	Up to $6 billion cumulative	Emerging markets, pipeline gains
Pessimistic	Increased competition, pricing pressure	~$4 billion cumulative	Market saturation, biosimilar entries

---

5. Policy and Regulatory Environment

Region	Key Policies	Impact on VEMLIDY	References
United States	FDA priority review for HBV	Facilitates faster access	[2]
European Union	EMA approvals; price controls	Affects pricing strategy	[3]
Emerging Markets	Gavi support, WHO guidelines	Expanding access	[4]

Conclusion: Investment Outlook for VEMLIDY

VEMLIDY’s established safety and efficacy profile positions it favorably within the chronic HBV and HIV markets. While growth has plateaued from its peak post-launch, upcoming pipeline developments, expanding global access, and evolving treatment guidelines spell continued revenue opportunities. Competitive pressures, particularly from generics and potential long-acting or combination therapies, pose risks that require strategic vigilance.

---

Key Takeaways

• Market Position: VEMLIDY remains a leading, high-growth antiviral asset with dominance in developed markets.
• Growth Drivers: Expanding indications, evolving guidelines, and emerging markets underpin its future sales trajectory.
• Risks: Patent expiry, biosimilar competition, and price pressures necessitate ongoing R&D and portfolio diversification.
• Financial Outlook: Anticipated steady revenue growth through 2028, with potential peaks driven by pipeline approvals.
• Investment Strategy: Focused on emerging markets expansion, pipeline development, and safeguarding against competitive erosion.

---

FAQs

1. What are the main factors influencing VEMLIDY's market growth?

Market growth is driven by its safety profile, increasing global HBV/HIV prevalence, guideline incorporation, and expanding access in emerging economies.

2. How does VEMLIDY compare to older formulations like TDF?

VEMLIDY offers similar antiviral efficacy but with superior renal and bone safety, enabling broader patient eligibility and adherence.

3. What are potential threats to VEMLIDY’s market share?

Generic formulations, long-acting injectables, and novel combination therapies pose competitive threats, especially in cost-sensitive markets.

4. How significant is VEMLIDY’s contribution to Gilead’s overall revenue?

While a key product, VEMLIDY accounts for approximately 4-5% of Gilead’s total revenue, with its impact growing due to expanding indications.

5. What are the regulatory prospects for VEMLIDY in emerging markets?

Global health initiatives and supportive policies favor broader approvals, though pricing and local regulatory hurdles vary.

---

References

[1] WHO. (2022). Hepatitis B factsheet.
[2] U.S. Food and Drug Administration. (2016). Approval of VEMLIDY for HIV.
[3] European Medicines Agency. (2020). VEMLIDY approval for HBV.
[4] Gavi, the Vaccine Alliance. (2021). Strategies for expanding access to HBV treatment.